{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T20:49:21Z","timestamp":1791751761190,"version":"4.3.4"},"reference-count":147,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["patient-research.elsevier.com","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.semarthrit.2013.11.004","type":"journal-article","created":{"date-parts":[[2013,11,16]],"date-time":"2013-11-16T15:47:56Z","timestamp":1384616876000},"page":"797-805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Thrombotic microangiopathies"],"prefix":"10.1016","volume":"43","author":[{"given":"Michael H.","family":"Rosove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2013.11.004_bib1","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00062752-200309000-00003","article-title":"The association of pregnancy with thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome","volume":"10","author":"George","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib3","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1537-2995.2009.02101.x","article-title":"Cognitive deficits after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Kennedy","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib5","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.tp.0000297998.33418.7e","article-title":"Hematopoietic stem cell transplantation: an autopsy study","volume":"85","author":"Siami","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib7","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1537-2995.2011.03125.x","article-title":"Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency","volume":"51","author":"Terrell","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1537-2995.2008.02082.x","article-title":"Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura","volume":"49","author":"Swisher","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib9","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib10","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00467-008-0872-4","article-title":"Complement and the atypical hemolytic uremic syndrome in children","volume":"23","author":"Loirat","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical practice guidelines for the management of atypical haemolytic uremic syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5482\/HAMO-13-04-0026","article-title":"Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry","volume":"2","author":"Mansouri Taleghani","year":"2013","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib15","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib16","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC\u2013HUS Registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib17","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case\u2013control study","volume":"345","author":"Menne","year":"2012","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat. Rev. Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib20","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume":"24","author":"Moschcowitz","year":"1924","journal-title":"Proc N Y Pathol Soc"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib21","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib22","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.1979.03290420035022","article-title":"Thrombotic thrombocytopenic purpura: a pathology review","volume":"241","author":"Berkowitz","year":"1979","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-65-1-37","article-title":"Pathology of the cardiac conduction system in thrombotic thrombocytopenic purpura","volume":"65","author":"Monto","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-91-3-357","article-title":"The heart and cardiac conduction system in thrombotic thrombocytopenic purpura","volume":"91","author":"Ridolfi","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1537-2995.2007.01534.x","article-title":"Clinical cardiac involvement in thrombotic thrombocytopenic purpura","volume":"48","author":"Hawkins","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib27","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0002-9343(78)90818-5","article-title":"Respiratory dysfunction in thrombotic thrombocytopenic purpura","volume":"65","author":"Bone","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jca.20226","article-title":"Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience","volume":"25","author":"Douglas","year":"2010","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenia purpura\u2013hemolytic uremic syndrome\u2014clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib32","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"Upshaw","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib33","unstructured":"OMIM No. 274150; \u3008www.ncbi.nlm.nih.gov\/omim\u3009."},{"key":"10.1016\/j.semarthrit.2013.11.004_bib34","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1538-7836.2012.04852.x","article-title":"A phenotype\u2013genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom","volume":"10","author":"Camilleri","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1538-7836.2010.03761.x","article-title":"ADAMTS-13 assays in thrombotic thrombocytopenic purpura","volume":"8","author":"Peyvandi","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib36","first-page":"905","article-title":"Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia","volume":"85","author":"Gasser","year":"1955","journal-title":"Schweiz Med Wochenschr"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib37","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1106483","article-title":"Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany","volume":"365","author":"Frank","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib38","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/cis255","article-title":"Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011.","volume":"54","author":"King","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0140-6736(83)91795-6","article-title":"Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools","volume":"1","author":"Karmali","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib40","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1056\/NEJM197804272981702","article-title":"Hemolytic-uremic syndrome after shigellosis","volume":"298","author":"Koster","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00858683","article-title":"Haemolytic uraemic syndrome associated with Yersinia enterocolitica infection","volume":"2","author":"Tsukahara","year":"1988","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib42","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3201\/eid1104.040739","article-title":"Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982\u20132002","volume":"11","author":"Rangel","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib43","series-title":"Horizons in medicine","first-page":"207","article-title":"Haemolytic uraemic syndrome","author":"Kavanagh","year":"2006"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib44","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/cid\/cis531","article-title":"An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children","volume":"55","author":"Loos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib45","series-title":"Hematology 2011","first-page":"9","article-title":"Too much of a good thing at the site of tissue injury: the instructive example of the complement system predisposing to thrombotic microangiopathy","author":"Liszewski","year":"2011"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib46","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","article-title":"Myocardial infarction is a complication of factor H-associated atypical HUS","volume":"25","author":"Sall\u00e9e","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib47","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/ndt\/gfq319","article-title":"Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation","volume":"25","author":"Loirat","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib48","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V56.2.302.302","article-title":"Thrombotic thrombocytopenic purpura: a ten-year experience","volume":"56","author":"Cuttner","year":"1980","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1055\/s-0032-1328894","article-title":"Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR)","volume":"38","author":"Jacob","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jacc.2007.04.093","article-title":"Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project","volume":"50","author":"Bennett","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib51","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib52","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11255-010-9755-2","article-title":"Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient","volume":"43","author":"Yilmaz","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clcc.2011.03.012","article-title":"Mitomycin-C-induced thrombotic thrombocytopenia purpura\/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era","volume":"10","author":"El-Ghazal","year":"2011","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib55","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib56","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib57","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.transproceed.2012.07.039","article-title":"De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival","volume":"44","author":"Caires","year":"2012","journal-title":"Transplant. Proc"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.tp.0000188140.50673.63","article-title":"Thrombotic microangiopathy after lung transplantation","volume":"81","author":"Hachem","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib59","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib60","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus\/sirolimus-based graft-versus-host-disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib61","series-title":"Cancer medicine","first-page":"864","article-title":"Hematologic complications of cancer and its treatment","author":"Rosove","year":"1984"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib62","series-title":"Progress in hemostasis and thrombosis, vol. 6","first-page":"203","article-title":"von Willebrand's disease","author":"Zimmerman","year":"1982"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib64","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood-2003-05-1505","article-title":"An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13","volume":"103","author":"Bowen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib66","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1182\/blood.V70.1.173.173","article-title":"Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals","volume":"70","author":"Battle","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib67","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation","volume":"78","author":"Moake","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib68","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V58.4.678.678","article-title":"The effects of ASA, PGE1, PGI2, and theophylline on the response of platelets subjected shear stress","volume":"58","author":"Hardwick","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib69","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib70","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","article-title":"The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease","volume":"108","author":"Jilma-Stohlawetz","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib71","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib72","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"Tsai","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib73","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2004-10-4097","article-title":"ADAMTS13 turns 3","volume":"106","author":"Levy","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib75","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1538-7836.2006.01959.x","article-title":"Human endothelial cells synthesize and release ADAMTS-13","volume":"4","author":"Turner","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib76","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0950-3536(98)80064-4","article-title":"Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura","volume":"11","author":"Furlan","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2011.051433","article-title":"Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura","volume":"97","author":"Froelich-Zahnd","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib78","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/jth.12319","article-title":"An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura","volume":"11","author":"Muia","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib79","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib80","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2002-03-0814","article-title":"Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin","volume":"101","author":"Reiter","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib81","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib82","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib83","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib84","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib86","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ajh.10457","article-title":"Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura","volume":"75","author":"Rick","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5414\/CNP64305","article-title":"Thrombotic thrombocytopenic purpura associated with polyarteritis nodosa","volume":"64","author":"Fujisaki","year":"2005","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3324\/haematol.11739","article-title":"ADAMTS13 and anti-ADAMTS13 antibodies are markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission","volume":"93","author":"Peyvandi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib89","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jca.20202","article-title":"Effect of blood group on idiopathic thrombotic thrombocytopenic purpura","volume":"24","author":"Zuberi","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib90","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1423-0410.2009.01164.x","article-title":"An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura","volume":"96","author":"Staropoli","year":"2009","journal-title":"Vox Sang"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib92","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib93","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib94","first-page":"1029","article-title":"Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome","volume":"88","author":"Lattuada","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib95","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jca.20194","article-title":"Is it quinine TTP\/HUS or quinine TMA? ADAMTS13 levels and implications for therapy","volume":"24","author":"Park","year":"2009","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib96","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/00007890-200210270-00003","article-title":"Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient","volume":"74","author":"Pham","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib97","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1532\/IJH97.05157","article-title":"High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogeneic hematopoietic stem cell transplantation","volume":"83","author":"Adachi","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib98","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1111\/j.1600-6143.2006.01574.x","article-title":"From humoral rejection to generalized thrombotic microangiopathy: role of acquired ADAMTS13 deficiency in a renal allograft recipient","volume":"6","author":"Ulinski","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib99","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-03-492421","article-title":"Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome","volume":"122","author":"Feng","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/j.ajkd.2004.10.018","article-title":"Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15","volume":"45","author":"Licht","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib101","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.med.59.060106.185110","article-title":"Complement regulatory genes and hemolytic uremic syndromes","volume":"59","author":"Kavanagh","year":"2008","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib102","first-page":"110","article-title":"Hypocomplementaemia due to a genetic deficiency of beta-1 H globulin","volume":"46","author":"Thompson","year":"1981","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib103","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/humu.20435","article-title":"The interactive factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and factor I mutations with structural models","volume":"28","author":"Saunders","year":"2007","journal-title":"Hum Mutat"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib104","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib105","doi-asserted-by":"crossref","first-page":"E1445","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"310","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib106","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib107","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib108","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0030-1262890","article-title":"Plasmatherapy in atypical hemolytic uremic syndrome","volume":"36","author":"Loirat","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib109","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00467-011-1943-5","article-title":"Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP","volume":"27","author":"Provaznikova","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib111","doi-asserted-by":"crossref","first-page":"e1001013","DOI":"10.1371\/journal.pmed.1001013","article-title":"Mutations in complement regulatory proteins predispose to preeclampsia","volume":"8","author":"Salmon","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib112","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-04-084533","article-title":"Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis and the HELLP syndrome","volume":"111","author":"Fang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib113","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","article-title":"Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"122","author":"Jodele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib114","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1128\/IAI.00274-13","article-title":"Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants","volume":"81","author":"Yosief","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib115","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1159\/000339494","article-title":"Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change","volume":"35","author":"Kidokoro","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib116","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.bbmt.2013.07.001","article-title":"Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide","volume":"19","author":"Carmona","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib117","first-page":"88","article-title":"Mitomycin-induced hemolytic uremic kidney: an experimental model in the rat","volume":"12","author":"Cattell","year":"1985","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib118","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.it.2004.11.007","article-title":"Immune complex-mediated tissue injury: a multistep paradigm","volume":"26","author":"Jancar","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib119","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajh\/4.8.700","article-title":"Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia","volume":"4","author":"Roberts","year":"1991","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0002-9378(99)70239-5","article-title":"Preeclampsia: an excessive maternal inflammatory response to pregnancy","volume":"180","author":"Redman","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib121","first-page":"219","article-title":"Exchange transfusion in the treatment of thrombotic thrombocytopenic purpura","volume":"13","author":"Bukowski","year":"1976","journal-title":"Semin Hematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura","volume":"50","author":"Bukowski","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib123","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM197712222972507","article-title":"Treatment of thrombotic thrombocytopenic purpura with plasma","volume":"297","author":"Byrnes","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib124","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib125","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.1981.03320170043028","article-title":"Hazard of platelet transfusion in thrombotic thrombocytopenic purpura","volume":"246","author":"Harkness","year":"1981","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib126","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jca.21279","article-title":"Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura","volume":"28","author":"Duffy","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib127","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-96-1-27","article-title":"Ineffectiveness of aspirin and dipyridamole in the treatment of thrombotic thrombocytopenic purpura","volume":"96","author":"Rosove","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib128","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ndt\/gfk042","article-title":"A new treatment for TTP?","volume":"21","author":"Fakhouri","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","article-title":"Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia","volume":"97","author":"Heidel","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5482\/HAMO-13-01-0004","article-title":"Treatment of thrombotic microangiopathy with a focus on new treatment options","volume":"2","author":"Kn\u00f6bl","year":"2013","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib131","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib132","doi-asserted-by":"crossref","first-page":"799","DOI":"10.7326\/0003-4819-82-6-799","article-title":"Phagocytosis of blood cells by splenic macrophages in thrombotic thrombocytopenic purpura","volume":"82","author":"Kadri","year":"1975","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib133","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinte.1985.00360050207040","article-title":"Splenectomy and extravascular platelet destruction in thrombotic thrombocytopenic purpura","volume":"145","author":"Rosove","year":"1985","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib134","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2141.2002.03809.x","article-title":"Successful treatment of congenital thrombotic thrombocytopenic purpura using the intermediate purity factor VIII concentrate BPL 8Y","volume":"119","author":"Lester","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib136","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib137","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/cid\/cis299","article-title":"Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis","volume":"55","author":"Wong","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib138","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","article-title":"Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome","volume":"8","author":"Hofer","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib139","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib140","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib141","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","article-title":"Neurologic involvement in atypical hemolytic uremic syndrome with successful treatment with eculizumab","volume":"28","author":"Gulleroglu","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib142","unstructured":"\u3008www.healthcare.uiowa.edu\/labs\/morl\/Gene_List_Complete.htm\u3009."},{"key":"10.1016\/j.semarthrit.2013.11.004_bib143","doi-asserted-by":"crossref","unstructured":"Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Noji H, et al. A rare genetic polymorphism in C5 confers poor response to the anti-C5 monoclonal antibody eculizumab by nine Japanese patients with PNH. 54th American Society of Hematology annual meeting and exposition, Atlanta, GA, December 8\u201311; 2012 [Abstract 3197].","DOI":"10.1182\/blood.V120.21.3197.3197"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib144","first-page":"271","article-title":"Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome following bone marrow transplantation","volume":"16","author":"Sarode","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib145","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ajh.20783","article-title":"Management of cancer-associated thrombotic microangiopathy: what is the right approach?","volume":"82","author":"Werner","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib146","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.transci.2012.03.027","article-title":"The TITAN trial\u2014assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura","volume":"46","author":"Holz","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.semarthrit.2013.11.004_bib147","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1586\/erc.10.154","article-title":"Targeting von Willebrand factor and platelet glycoprotein Ib receptor","volume":"8","author":"Firbas","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213002473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213002473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T14:05:00Z","timestamp":1716127500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017213002473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":147,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0049017213002473"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2013.11.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic microangiopathies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2013.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}